Dairy Cow Veterinary Pharmaceuticals

Zoetis Inc. (Parsippany NJ; NYSE: ZTS; ~$8.5B revenue FY2024; founded 2013 as Pfizer Animal Health spinoff) is the world's largest animal health company — ~20% global animal health market — and the dominant US dairy pharmaceutical supplier. Zoetis's dairy-relevant products include Lutalyse (dinoprost tromethamine — a PGF2α prostaglandin used for estrus synchronization, abortion, and pyometra treatment), CIDR (controlled internal drug release — intravaginal progesterone device for reproductive synchronization), Excede (ceftiofur crystalline free acid — third-generation cephalosporin for bovine respiratory disease), Draxxin (tulathromycin — macrolide antibiotic), and Improvac (GnRH immunocastration vaccine). Zoetis was the animal health division of Pfizer — the largest animal health company in the world hidden inside the world's largest pharmaceutical company. The 2013 IPO (raising $2.2B) revealed the scale of veterinary pharmaceutical concentration for the first time. Zoetis operates manufacturing in Kalamazoo MI, Lincoln NE, Guarulhos Brazil, Olot Spain, and Suzhou China.

Elanco Animal Health Inc. (Greenfield IN; NYSE: ELAN; ~$4.4B revenue FY2024; spun off from Eli Lilly in 2018 IPO; acquired Bayer Animal Health 2020 for $7.6B) is the #2 or #3 animal health company globally behind Zoetis and closely competing with Boehringer Ingelheim. The Bayer Animal Health acquisition added major dairy-relevant products: Baytril (enrofloxacin — fluoroquinolone antibiotic), Advocate/Advantage (parasiticides), and Seresto. Elanco's legacy Lilly Animal Health products include Posilac (recombinant bovine somatotropin — rBST — the controversial bovine growth hormone) and mastitis treatment products. Elanco is a major supplier of intramammary mastitis treatments (Pirsue/pirlimycin, ToDAY/cloxacillin dry cow tubes) for the US dairy industry. The 2020 Bayer Animal Health acquisition made Elanco a genuine global challenger to Zoetis but also burdened Elanco with significant debt ($5.4B), resulting in ongoing cost-cutting and divestitures.

Merck Animal Health (Madison NJ; division of Merck & Co.; ~$5.5B revenue) manufactures AviPro brand avian influenza and Newcastle disease vaccines for commercial poultry. Products sold as MSD Animal Health outside North America. Merck Animal Health is the third-largest animal health company globally. De Soto KS biologics manufacturing site.

Boehringer Ingelheim Animal Health (Ingelheim am Rhein, Germany; private; ~€4B animal health revenue) manufactures VECTORMUNE HVT-AI recombinant poultry vaccines using herpesvirus of turkeys (HVT) as a vector. The recombinant platform simultaneously protects against Marek's disease and avian influenza. US manufacturing at Pope Valley CA and Duluth GA. Boehringer Ingelheim is the second-largest animal health company globally.

Phibro Animal Health Corporation (Teaneck NJ; NASDAQ: PAHC; ~$1B revenue) manufactures POULVAC brand poultry vaccines (acquired from Fort Dodge/Zoetis divestiture) along with medicated feed additives and nutritional products. Phibro serves commercial poultry producers globally with AI vaccines, Newcastle disease biologics, and coccidiostats.

HIPRA (Amer, Girona Catalonia Spain; private; ~€500M estimated revenue) is a European-focused animal health company with strong dairy vaccine and reproductive pharmaceutical product lines. Dairy-relevant products include: HIPRABOVIS (bovine respiratory disease vaccine complex), FERTILINE (GnRH analog — gonadorelin — for dairy reproductive synchronization protocols), FERTAGYL/HIPRELIN (GnRH analog products for reproductive induction in dairy herds), and Pyrocalma (antipyretic for cattle). HIPRA is the leading European dairy reproductive hormone supplier outside the major US and German companies. HIPRA's gonadorelin products compete directly with Zoetis's Cystorelin (gonadorelin) and Elanco's Factrel (gonadorelin) in EU dairy operations. HIPRA's human vaccine division (COVID-19 mRNA vaccine PHH-1V) gained global attention in 2022-2023 — revealing that this primarily-dairy-pharmaceutical Spanish company had independently developed a human COVID vaccine using the same immunology research infrastructure.